Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.16T
Market cap1.16T
Price-Earnings ratio
43.20
Price-Earnings ratio43.20
Dividend yield
0.54%
Dividend yield0.54%
Average volume
3.55M
Average volume3.55M
High today
$1,249.45
High today$1,249.45
Low today
$1,216.00
Low today$1,216.00
Open price
$1,232.00
Open price$1,232.00
Volume
1.92M
Volume1.92M
52 Week high
$1,249.45
52 Week high$1,249.45
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

As of today, Eli Lilly(LLY) shares are valued at $1,235.60. The company's market cap stands at 1.16T, with a P/E ratio of 43.20 and a dividend yield of 0.54%.

During the trading session on 2026-07-07, Eli Lilly(LLY) shares reached a daily high of $1,249.45 and a low of $1,216.00. At a current price of $1,235.60, the stock is +1.6% higher than the low and still -1.1% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 1.92M, versus its average volume of 3.55M.

The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.

The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.

LLY News

Nasdaq 44m
U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend

Key Points Eli Lilly and Intuitive Surgical are top players in their respective corners of the healthcare market. Both companies are highly innovative and boa...

U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend
Investor's Business Daily 2h
Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback - Investor's Business Daily

...

Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback - Investor's Business Daily
The Wall Street Journal 3h
Health Care Roundup: Market Talk

Yves Herman / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Health Care Roundup: Market Talk

Analyst ratings

84%

of 31 ratings
Buy
83.9%
Hold
9.7%
Sell
6.5%

More LLY News

Nasdaq 4h
Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy?

Key Points Eli Lilly's growth rate has been accelerating over the past year due to its GLP-1 drugs. The recent approval of its GLP-1 pill, Foundayo, could off...

Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy?
TipRanks 6h
Health Canada approves Eli Lilly’s Mounjaro for use in children 10 years old

Eli Lilly (LLY) Canada announced that Mounjaro is now indicated as an adjunct to diet and exercise to improve glycemic control in pediatric patients living with...

Nasdaq 7h
Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years.

Key Points The obesity drug industry is likely a decade-long tailwind for Eli Lilly's business. Foundayo and Retatrutide could cement a decade of growth. The...

Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years.
TipRanks 8h
Transcenta Returns Two Lilly-Licensed Compounds in US$4 Million Deal, Retains Blosozumab Rights

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Zacks 9h
The Zacks Analyst Blog Highlights Eli Lilly, HSBC, Palantir and CBL & Associates

This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herei...

The Zacks Analyst Blog Highlights Eli Lilly, HSBC, Palantir and CBL & Associates
Simply Wall St 13h
Eli Lilly Could Be 19% Undervalued Following Medicare GLP 1 Expansion

The latest move in Eli Lilly (LLY) stock comes as the Medicare GLP-1 Bridge program opens wider access to its weight management drugs, alongside strong reported...

Eli Lilly Could Be 19% Undervalued Following Medicare GLP 1 Expansion
Nasdaq 1d
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Key Points Eli Lilly and dominance in weight loss and diabetes treatments continues to fuel massive revenue growth. Teva Pharmaceutical Industries offers a va...

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.